• Home
  • Search Results

Research Studies

UNC-Chapel Hill Lineberger Comprehensive Cancer Center

268 studies match your search
Open

Phase 2 study of isatuximab plus lenalidomide and dexamethasone in highly toxicity-vulnerable subjects with newly diagnosed multiple myeloma

Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Relapsed or Refractory Multiple Myeloma: Safety and Dose Optimization of ABBV-383

Have you been diagnosed with multiple myeloma that has not responded to treatment or has come back after treatment? If so, you may be able to take part in a research study looking at the safety and efficacy of giving a new drug called ABBV-383 to patients with relapsed/refractory multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Phase 1 Trials (all cancers), Multiple Myeloma)

LCCC 2054: Obesity, Frailty, and Age-Related Responses to Surgery and Treatment in Endometrial Cancer Patients

The purpose of this observational study is to follow Endometrial Cancer patients through standard of care treatment of their Endometrial Cancer and collect biomedical and patient reported outcomes data.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
  • Women's Health

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

The purpose of this study is to compare the effectiveness of the drug megestrol alone, or combined with metformin, on the growth of Endometrial Intraepithelial Neoplasia.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
Open

DORA

Have you been diagnosed with Metastatic Castration-Resistant Prostate Cancer. If so, you may be able to take part in a research study looking at the safety of giving Docetaxel vs Docetaxel and Radium-223 to patients.

Age & Gender
  • 18 years ~ 99 years
  • Male
Study Interest
  • Cancer (Prostate)
  • Sexual and/or Reproductive Health
  • Urinary and Bladder
  • Men's Health
Open

NRG-GY026: Testing the addition of HERCEPTIN HYLECTA or PHESGO to the usual chemotherapy for HER2 positive endometrial serous carcinoma or carcinosarcoma

Have you been diagnosed with uterine cancer called endometrial serous carcinoma or carcinosarcoma? If so, you may be able to take part in a research study to test if adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs could prevent your cancer from returning or shrink your cancer.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial))
Open

Lung and Head/Neck Cancer Registry

Do you have known or suspected lung and/or head and neck cancer? Are you scheduled for a tumor biopsy? If so, you may be able to participate in a research registry aimed at learning more about lung and head/neck cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck, Lung)
Open

Blood Test to Predict Recurrence Across Early-Stage Cancers

Are you receiving initial treatment for non-small cell lung cancer or invasive squamous cell carcinoma of the head and neck and want to participate in research that aims to improve treatment and care of future patients with the same diagnosis? If so, you may be able to participate in a study for an investigational blood test to predict whether your cancer will come back.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck, Lung)
Open

Phase II Study of Trilaciclib and Lurbinectidin

Have you been diagnosed with small cell lung cancer? Is your current treatment no longer working in controlling your cancer? If so, you may be able to take part in a research study looking at giving trilaciclib to help minimize the side effects of lurbinectedin.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Lung)
  • Lungs and Breathing

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in Oncology

This is a research study to investigate how collecting information about treatment-related side effects directly from patients can help manage the side effects associated with certain oral chemotherapies in patients with metastatic renal cell carcinoma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Kidney)
Visit Location
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research